Berenil acts as a poison of eukaryotic topoisomerase II  by Portugal, José
FEBS Letters 344 (1994) 136-138 LETTERS 
ELSEVIER 
FEBS 13978 
Berenil acts as a poison of eukaryotic topoisomerase II
JosC Portugal* 
Departamento de Biologia Molecular y Celular, Consejo Superior de Investigaciones Cientificas, J. Girona-Salgado, 18-26, 
08034 Barcelona. Spain 
Received 7 January 1994; revised version received 4 March 1994 
Abstract 
The ability of the anti-trypanosomal drug berenil to interfere with the activities of eukaryotic type II topoisomerases is evaluated using two different 
types of reactions catalyzed by the enzyme: the relaxation of naturally supercoiled DNA and the decatenation of kinetoplast DNA (kDNA). The 
results indicate that berenil acts as an inhibitor of the catalytic activity, but the inhibiting ability appears to be smaller than for other minor-groove 
binding ligands. 
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1. Introduction 
Berenil is a synthetic drug that is effective against 
animal trypanosomiasis [ 1,2]. The pharmacological ef- 
fect of berenil in vivo has been related [l] to its preference 
for kinetoplast DNA (kDNA). It is well established that 
berenil (Fig. 1) interacts preferentially with adenine plus 
thymine-rich DNAs, binding in the minor groove to se- 
quences which are about four base-pairs long, with a 
certain preference for alternating AT-sites [3-61. It has 
been described that minor-groove binding ligands might 
be topoisomerase II poisons [7,8]. However, more de- 
tailed studies are needed not only to determine whether 
berenil can act in the same way as other AT-binding 
ligands, but also to find out if a potential target for this 
drug could be a topoisomerase involved in the topolog- 
ical manipulation of DNA in the mitochondria, where 
the kDNA is located, and whether the effect on the 
topoisomerase would be, therefore, responsible for the 
pharmacological and toxic effects of the drug. Various 
topoisomerase activities have been detected in the mito- 
chondria, one of which is a type II topoisomerase which 
requires ATP and decatenates closed circular kDNA [9], 
thus sharing functions with the eukaryotic type II topoi- 
somerases. The possibility has been raised that an unu- 
sual topoisomerase activity in trypanosomal mitochon- 
dria might explain why berenil, and other antitrypano- 
somal drugs, preferentially attack the mitochondrial 
DNA [8]. 
In this study, the effects of berenil are characterized 
using two different types of reaction catalyzed by eukar- 
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yotic topoisomerase II: the relaxation of naturally su- 
percoiled DNA and the decatenation of kDNA. 
2. Materials and methods 
2.1. Materials 
Berenil was kindly provided by Hoechst-Iberica (Spain) and was 
freshly prepared as a 1 mM stock solution in Tris-HCl, pH 7.4 contain- 
ing 20 mM NaCl, and diluted to the required concentration just before 
use. Calf thymus type II topoisomerase and catenated kinetoplast DNA 
were purchased from TopoGen, Inc. (Columbus, USA). Plasmid 
pBR322 was purchased from Boehringer Mannheim. The pBR322 sam- 
ple was analyzed in 1% agarose and was found to contain about 80% 
of supercoiled DNA. 
2.2. Relaxation of pBR322 
Reactions contained 0.125 pg of pBR322 DNA in 50 mM Tris-HCl, 
pH 7.8, 1 mM ATP, 1 mM dithiothreitol, 50 mM KCl, 5 mM MgCl,, 
30 pg/ml bovine serum albumin and 1 Unit of enzyme in a final volume 
of 20 ~1. Reactions were performed in the absence or presence of 
berenil, at the concentrations indicated in the figures, and terminated, 
after 15 min incubation at 37”C, with 0.5% sodium dodecyl sulfate, 50 
&ml Proteinase K and 10 mM EDTA and incubation for 30 min at 
37°C. 
2.3. Decatenation of kDNA 
Reaction mixtures (20 ~1 final volume) contained 0.100 fig of kDNA 
and 1.5 Units of topoisomerase II in 30 mM Tris-HCl pH 7.8, 50 mM 
KCl, 5 mM MgCl,, 1 mM ATP, 1 mM dithiothreitol and 30 &ml 
bovine serum albumin. Following 30 min incubation at 37°C the reac- 
tions were terminated as described above. 
2.4. Electrophoretic analysis of the topoisomerase II activity in the 
presence of berenil 
After addition of 0.1 volumes of loading dye (50% glycerol, 0.03% 
Bromophenol blue), the eukaryotic topoisomerase II products were 
separated on 1% agarose gel in Tris-Borate-EDTA buffer at 100 V for 
about one hour. Separation of relaxed circular DNA from the co- 
migrating nicked DNA was accomplished on a gel containing 30 /&/ml 
chloroquine, run at 40 V overnight. Gels were stained with ethidium 
bromide (0.5 ,@ml) for 45 min, destained in water and photographed. 
For quantitative purposes, the photographic negatives were scanned 
and the amount of DNA in each band determined using a computerized 
Molecular Dynamics laser densitometer. 
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Fig. 1. Chemical structure of berenil. 
3. Results and discussion 
Fig. 2A displays the effects of berenil on the relaxation 
of pBR3222 DNA by calf-thymus topoisomerase II. In 
the absence of the drug (lane +) the topoisomerase con- 
verted supercoiled DNA into relaxed circular DNA, 
which, in the experimental conditions, comigrated with 
the nicked DNA. The addition of different concentra- 
tions of berenil (between 2 and 200 ,LLM) produced a 
progressive inhibition of the topoisomerase II-induced 
topological changes in DNA, though a complete inhibi- 
tion of the enzyme activity was not attained even at 
concentrations around 200 PM. In contrast, other 
minor-groove binding drugs are able to produce com- 
plete enzyme inhibition even at smaller concentrations 
[7]. These results suggest that berenil reduces but does 
not completely inhibit the reaction of topoisomerase II. 
An agarose gel containing chloroquine was used (Fig. 
2B) to separate the co-migrating relaxed circular (1~) and 
nicked (II) forms, thus allowing correct quantification of 
the relaxation catalyzed by the topoisomerase. This gel 
confirmed that the amount of nicked DNA remained 
mostly unchanged in the presence of berenil and topoi- 
somerase II. Quantification of the experimental data re- 
veals that a 5 1% inhibition is obtained at 20 PM berenil, 
a concentration used in footprinting experiments to dis- 
close the preferred binding sites [3,4], while about 90% 
inhibition was observed at 200 ,uM berenil. 
The decatenation of kDNA was used to study the 
effects of berenil on topoisomerase II. Densitometric 
profiles obtained from a typical agarose gel pattern are 
shown in Fig. 3. Addition of berenil resulted in a drug- 
dependent decrease in the release of monomers, which is 
evident at approx. 20 PM, or at larger concentrations. 
The experiments to analyze the effects of berenil on the 
decatenation activity of topoisomerase II (Fig. 3) were 
performed in conditions chosen for the detection of in- 
hibition, but low concentrations of the drug, below 20 
PM, seemed to stimulate the release of uncatenated cir- 
cles, while increasing berenil concentrations inhibited the 
production of monomers (right panel in Fig. 3). In fact, 
a complete inhibition of the decatenation procedure was 
not obtained, even at concentrations around 100 PM. 
Once again, the inhibitory effect was smaller than that 
seen for distamycin or other minor-groove binding li- 
gands [7]. 
The influence of various reaction conditions on berenil 
action, including the order of addition in the reaction 
mixture, was also examined. For example the drug was 
equilibrated with supercoiled pBR322 DNA, for 20 min 
at 37°C prior to the addition of the enzyme, but no 
increment in the inhibition was observed. Results in Fig. 
2 show that drug concentrations up to 50 ,LLM, produced 
distinct intermediate bands, indicating that the topoi- 
somerase initiates, but does not complete, the relaxation 
of several supercoiled molecules. Results presented in 
Figs. 2B and 3 suggest that DNA topoisomerase II is 
unable to interact with DNA sites where the minor- 
groove is occupied by berenil. Furthermore, berenil is a 
relatively weak inhibitor of type II eukaryotic topoisom- 
erase if compared with other minor-groove ligands [7]. 
The difference might be related with the lower affinity of 
berenil for A+T-rich DNAs compared to distamycin or 
netropsin [lo]. 
Eukaryotic topoisomerase II poisons produce a rapid 
inhibition of DNA replication [ll]. The replication of 
kDNA in the trypanosomatids, including those involved 
in tropical diseases, requires topological manipulations 
of this peculiar DNA [12]. It has been described that 
before the replication takes place, all the minicircles 
within a network are covalently closed. Berenil might be 
capable of inhibiting (Fig. 3) the release of minicircles 
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Fig. 2. Effects of berenil on the relaxation of supercoiled pBR322 DNA by topoisomerase II. Electrophoretic patterns without (lane -) and with 
(lane +) topoisomerase II, and in the presence of the indicated concentrations of berenil. (A): Gel stained with ethidium bromide; (B) Gel run in the 
presence of 30 &ml chloroquine. Forms I, IR and II represent highly supercoiled, relaxed circular and nicked DNA respectively. 
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Fig. 3. Effects of berenil on the catalytic activity of topoisomerase II in a decatenation assay using catenated kinetoplast DNA. Cat. and Mon. 
correspond to catenated and monomer (decatenated) kDNA. The figure shows densitometric profiles (a) to (g) obtained from electrophoretic patterns 
without (a) and with topoisomerase II (b-g), and in the presence of berenil at the concentrations indicated in the right panel, which displays a 
quantification of the percentage of monomer (decatenated) kDNA in the samples. 
To elucidate the exact mechanism by which berenil acts 
as a poison of topisomerase II will require further con- 
sideration using complementary experimental ap- 
proaches to those presented here. The relatively small 
effect of berenil (Figs. 2 and 3), when compared with 
other ligands devoid of antitrypanosomal effect in vivo 
[7], indirectly indicates that the type II topoisomerase 
activity present in mitochondria [9] should display some 
kinetic peculiarities which would make it more suscepti- 
ble to berenil than to other drugs. 
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